This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the comfort when using this website, are used for direct advertising or to facilitate interaction with other websites and social networks, are only set with your consent.
Configuration
Technically required
These cookies are necessary for the basic functions of the shop.
"Allow all cookies" cookie
"Decline all cookies" cookie
CSRF token
Cookie preferences
Currency change
Customer-specific caching
FACT-Finder tracking
Individual prices
Selected shop
Session
Comfort functions
These cookies are used to make the shopping experience even more appealing, for example for the recognition of the visitor.
Note
Show the facebook fanpage in the right blod sidebar
Statistics & Tracking
Affiliate program
Conversion and usertracking via Google Tag Manager
RVX-297 is an inhibitor of the bromodomain and extra-terminal domain (BET) family protein bromodomain 2 (BD2). It inhibits BD2 in bromodomain-containing protein 2 (BRD2), BRD3, and BRD4, (IC50s = 0.08, 0.05, and 0.02 µM, respectively) and is selective for BD2 over BD1 (IC50s = 3.76, 2.34, and 1.16 µM for BRD2, BRD3, and BRD4, respectively), as well as CREB-binding protein (CREBBP) and p300 (IC50s = >50 µM for both). RVX-297 (10 and 30 µM) decreases levels of the mRNAs encoding IL-6 and vascular cell adhesion molecule-1 (VCAM-1) in primary synovial fibroblasts isolated from patients with rheumatoid arthritis. It prevents LPS-induced increases in IL-6 and Ifn-gamma serum levels in a mouse model of LPS-induced endotoxemia when administered at a dose of 75 mg/kg. RVX-297 (25, 50, and 75 mg/kg twice per day) inhibits collagen-induced increases in ankle and knee diameter, cartilage damage, the ankle tissue levels of mRNA encoding IL-1beta, matrix metalloproteinase-3 (Mmp-3), Mmp-13, and Rankl, and ankle joint protein levels of IL-6 and VCAM-1 in a rat model of collagen-induced rheumatoid arthritis. It improves gait and mobility and reverses body weight loss, as well as decreases the number of spinal cord inflammatory foci and apoptotic cells and reduces spinal nerve demyelination in a mouse model of experimental autoimmune encephalomyelitis (EAE) when administered at doses of 75 and 125 mg/kg per day.Formal Name: 2-[3,5-dimethyl-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-5,7-dimethoxy-4(3H)-quinazolinone. CAS Number: 1044871-04-6. Molecular Formula: C24H29N3O4. Formula Weight: 423.5. Purity: >95%. Formulation: (Request formulation change), A solid. Solubility: Methanol: Soluble. SMILES: O=C1N=C(C2=CC(C)=C(OCCN3CCCC3)C(C)=C2)NC4=C1C(OC)=CC(OC)=C4. InChi Code: InChI=1S/C24H29N3O4/c1-15-11-17(12-16(2)22(15)31-10-9-27-7-5-6-8-27)23-25-19-13-18(29-3)14-20(30-4)21(19)24(28)26-23/h11-14H,5-10H2,1-4H3,(H,25,26,28). InChi Key: PQZDYFRDRHRZGF-UHFFFAOYSA-N.
This website uses cookies, which are necessary for the technical operation of the website and are always set. Other cookies, which increase the usability of this website, serve for direct advertising or simplify interaction with other websites and social networks, will only be used with your consent.
More information